LRRK2: An éminence grise of Wnt-mediated neurogenesis?

Frontiers in Cellular Neuroscience

Volumn , Issue MAY, 2013, Pages

  Berwick, Daniel C ^a   Harvey, Kirsten ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

DVL; GSK3; LRP6; LRRK2; Neurogenesis; Parkinson's disease; Wnt signaling

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; DISHEVELLED 2; DISHEVELLED 3; DISHEVELLED PROTEIN; EZRIN; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3; LEUCINE RICH REPEAT KINASE 2; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MICROTUBULE ASSOCIATED PROTEIN; MOESIN; PESTICIDE; RAB PROTEIN; RAB5 PROTEIN; RAB7 PROTEIN; RADIXIN; TAU PROTEIN; UNCLASSIFIED DRUG; WNT3A PROTEIN; WNT7A PROTEIN;

ACTIN FILAMENT; ALZHEIMER DISEASE; ARTICLE; AUTISM; CORPUS STRIATUM; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; MACROAUTOPHAGY; MESENCEPHALON; MICROTUBULE; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PARK2 GENE; PARK8 GENE; PARKINSON DISEASE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TELENCEPHALON; WNT SIGNALING PATHWAY;

EID: 84878091235     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2013.00082     Document Type: Article

References (135)

1. A. Ahmad-Annuar, L. Ciani, I. Simeonidis, J. Herreros, N.B. Fredj, S.B. Rosso, A. Hall, S. Brickley, and P.C. Salinas (2006). Signaling across the synapse: a role for Wnt and Dishevelled in presynaptic assembly and neurotransmitter release. J Cell Biol 174, 127-39.
2. J. Alegre-Abarrategui, H. Christian, M.M. Lufino, R. Mutihac, L.L. Venda, O. Ansorge, and R. Wade-Martins (2009). LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 18, 4022-34.
3. L. Avrahami, D. Farfara, M. Shaham-Kol, R. Vassar, D. Frenkel, and H. Eldar-Finkelman (2013). Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J Biol Chem 288, 1295-306.
4. Z. Berger, K.A. Smith, and M.J. Lavoie (2010). Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 49, 5511-23.
5. D.C. Berwick, and K. Harvey (2011). LRRK2 signaling pathways: the key to unlocking neurodegeneration? Trends Cell Biol 21, 257-65.
6. D.C. Berwick, and K. Harvey (2012a). LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6. Hum Mol Genet 21, 4966-79.
7. D.C. Berwick, and K. Harvey (2012b). The importance of Wnt signalling for neurodegeneration in Parkinson's disease. Biochem Soc Trans 40, 1123-8.
8. A. Biosa, A. Trancikova, L. Civiero, L. Glauser, L. Bubacco, E. Greggio, and D.J. Moore (2012). GTPase Activity Regulates Kinase Activity and Cellular Phenotypes of Parkinson's Disease-Associated LRRK2. Hum Mol Genet.
9. S. Biskup, D.J. Moore, F. Celsi, S. Higashi, A.B. West, S.A. Andrabi, K. Kurkinen, S.W. Yu, J.M. Savitt, H.J. Waldvogel, R.L. Faull, P.C. Emson, R. Torp, O.P. Ottersen, T.M. Dawson, and V.L. Dawson (2006). Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60, 557-69.
10. J.T. Blitzer, and R. Nusse (2006). A critical role for endocytosis in Wnt signaling. BMC Cell Biol 7, 28.
11. V. Brault, R. Moore, S. Kutsch, M. Ishibashi, D.H. Rowitch, A.P. McMahon, L. Sommer, O. Boussadia, and R. Kemler (2001). Inactivation of the beta-catenin gene by Wnt1-Cremediated deletion results in dramatic brain malformation and failure of craniofacial development. Development 128, 1253-64.
12. I. Cantuti-Castelvetri, C. Keller-McGandy, B. Bouzou, G. Asteris, T.W. Clark, M.P. Frosch, and D.G. Standaert (2007). Effects of gender on nigral gene expression and parkinson disease. Neurobiol Dis 26, 606-14.
13. A.C. Carpenter, S. Rao, J.M. Wells, K. Campbell, and R.A. Lang (2010). Generation of mice with a conditional null allele for Wntless. Genesis 48, 554-8.
14. G. Castelo-Branco, E.R. Andersson, E. Minina, K.M. Sousa, D. Ribeiro, C. Kokubu, K. Imai, N. Prakash, W. Wurst, and E. Arenas (2010). Delayed dopaminergic neuron differentiation in Lrp6 mutant mice. Dev Dyn 239, 211-21.
15. G. Castelo-Branco, N. Rawal, and E. Arenas (2004). GSK-3beta inhibition/beta-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. J Cell Sci 117, 5731-7.
16. G. Castelo-Branco, J. Wagner, F.J. Rodriguez, J. Kele, K. Sousa, N. Rawal, H.A. Pasolli, E. Fuchs, J. Kitajewski, and E. Arenas (2003). Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci U S A 100, 12747-52.
17. F. Cecconi, S. Di Bartolomeo, R. Nardacci, C. Fuoco, M. Corazzari, L. Giunta, A. Romagnoli, A. Stoykova, K. Chowdhury, G.M. Fimia, and M. Piacentini (2007). A novel role for autophagy in neurodevelopment. Autophagy 3, 506-8.
18. F. Cecconi, and B. Levine (2008). The role of autophagy in mammalian development: cell makeover rather than cell death. Dev Cell 15, 344-57.
19. D. Chan, A. Citro, J.M. Cordy, G.C. Shen, and B. Wolozin (2011). Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J Biol Chem 286, 16140-9.
20. H.W. Chang, Y.S. Lee, H.Y. Nam, M. Han, H.J. Kim, S.Y. Moon, Hyesungjeon, J.J. Park, T.E. Carey, S.E. Chang, S.W. Kim, and S.Y. Kim (2012). Knockdown of β-catenin controls both apoptotic and autophagic cell death through LKB1/AMPK signaling in head and neck squamous cell carcinoma cell lines. Cell Signal.
21. S.J. Cherra, E. Steer, A.M. Gusdon, K. Kiselyov, and C.T. Chu (2012). Mutant LRRK2 Elicits Calcium Imbalance and Depletion of Dendritic Mitochondria in Neurons. Am J Pathol.
22. H.J. Cho, G. Liu, S.M. Jin, L. Parisiadou, C. Xie, J. Yu, L. Sun, B. Ma, J. Ding, R. Vancraenenbroeck, E. Lobbestael, V. Baekelandt, J.M. Taymans, P. He, J.C. Troncoso, Y. Shen, and H. Cai (2012). MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet.
23. L. Ciani, O. Krylova, M.J. Smalley, T.C. Dale, and P.C. Salinas (2004). A divergent canonical WNT-signaling pathway regulates microtubule dynamics: dishevelled signals locally to stabilize microtubules. J Cell Biol 164, 243-53.
24. P. Codogno, M. Mehrpour, and T. Proikas-Cezanne (2012). Canonical and non-canonical autophagy: variations on a common theme of self-eating? Nat Rev Mol Cell Biol 13, 7-12.
25. A.R. Cole, A. Knebel, N.A. Morrice, L.A. Robertson, A.J. Irving, C.N. Connolly, and C. Sutherland (2004). GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem 279, 50176-80.
26. E.K. Davis, Y. Zou, and A. Ghosh (2008). Wnts acting through canonical and noncanonical signaling pathways exert opposite effects on hippocampal synapse formation. Neural Dev 3, 32.
27. G.V. De Ferrari, and R.T. Moon (2006). The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene 25, 7545-53.
28. R. Dobrowolski, and E.M. De Robertis (2012). Endocytic control of growth factor signalling: multivesicular bodies as signalling organelles. Nat Rev Mol Cell Biol 13, 53-60.
29. M.W. Dodson, T. Zhang, C. Jiang, S. Chen, and M. Guo (2012). Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet 21, 1350-63.
30. Y. Dun, G. Li, Y. Yang, Z. Xiong, M. Feng, M. Wang, Y. Zhang, J. Xiang, and R. Ma (2012). Inhibition of the canonical Wnt pathway by Dickkopf-1 contributes to the neurodegeneration in 6-OHDA-lesioned rats. Neurosci Lett 525, 83-8.
31. N. Dzamko, M. Deak, F. Hentati, A.D. Reith, A.R. Prescott, D.R. Alessi, and R.J. Nichols (2010). Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 430, 405-13.
32. J.C. Dächsel, B. Behrouz, M. Yue, J.E. Beevers, H.L. Melrose, and M.J. Farrer (2010). A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism Relat Disord 16, 650-5.
33. G.G. Farías, J.A. Godoy, W. Cerpa, L. Varela-Nallar, and N.C. Inestrosa (2010). Wnt signaling modulates preand postsynaptic maturation: therapeutic considerations. Dev Dyn 239, 94-101.
34. G.G. Farías, A.S. Vallés, M. Colombres, J.A. Godoy, E.M. Toledo, R.J. Lukas, F.J. Barrantes, and N.C. Inestrosa (2007). Wnt-7a induces presynaptic colocalization of alpha 7-nicotinic acetylcholine receptors and adenomatous polyposis coli in hippocampal neurons. J Neurosci 27, 5313-25.
35. A. Ferree, M. Guillily, H. Li, K. Smith, A. Takashima, R. Squillace, M. Weigele, J.J. Collins, and B. Wolozin (2011). Regulation of Physiologic Actions of LRRK2: Focus on Autophagy. Neurodegener Dis.
36. J.L. Freese, D. Pino, and S.J. Pleasure (2010). Wnt signaling in development and disease. Neurobiol Dis 38, 148-53.
37. P.N. Gandhi, X. Wang, X. Zhu, S.G. Chen, and A.L. Wilson-Delfosse (2008). The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 86, 1711-20.
38. T. Gasser (2010). Identifying PD-causing genes and genetic susceptibility factors: current approaches and future prospects. Prog Brain Res 183, 3-20.
39. F. Gillardon (2009a). Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro. Neuroscience 163, 533-9.
40. F. Gillardon (2009b). Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration? J Neurochem 110, 1514-22.
41. C.J. Gloeckner, N. Kinkl, A. Schumacher, R.J. Braun, E. O'Neill, T. Meitinger, W. Kolch, H. Prokisch, and M. Ueffing (2006). The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15, 223-32.
42. S. Gollamudi, A. Johri, N.Y. Calingasan, L. Yang, O. Elemento, and M.F. Beal (2012). Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease. PLoS One 7, e36191.
43. K. Gotthardt, M. Weyand, A. Kortholt, P.J. Van Haastert, and A. Wittinghofer (2008). Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J 27, 2352.
44. E. Greggio, and M.R. Cookson (2009). Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 1.
45. E. Greggio, S. Jain, A. Kingsbury, R. Bandopadhyay, P. Lewis, A. Kaganovich, M.P. van der Brug, A. Beilina, J. Blackinton, K.J. Thomas, R. Ahmad, D.W. Miller, S. Kesavapany, A. Singleton, A. Lees, R.J. Harvey, K. Harvey, and M.R. Cookson (2006). Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23, 329-41.
46. E. Greggio, I. Zambrano, A. Kaganovich, A. Beilina, J.M. Taymans, V. Daniëls, P. Lewis, S. Jain, J. Ding, A. Syed, K.J. Thomas, V. Baekelandt, and M.R. Cookson (2008). The Parkinson diseaseassociated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283, 16906-14.
47. P. Gómez-Suaga, B. Luzón-Toro, D. Churamani, L. Zhang, D. Bloor-Young, S. Patel, P.G. Woodman, G.C. Churchill, and S. Hilfiker (2012). Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet 21, 511-25.
48. A.C. Hall, F.R. Lucas, and P.C. Salinas (2000). Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell 100, 525-35.
49. S. Hassin-Baer, Y. Laitman, E. Azizi, I. Molchadski, G. Galore-Haskel, F. Barak, O.S. Cohen, and E. Friedman (2009). The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J Neurol 256, 483-7.
50. T. Hatano, S. Kubo, S. Imai, M. Maeda, K. Ishikawa, Y. Mizuno, and N. Hattori (2007). Leucinerich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 16, 678-90.
51. H.Y. Heo, K.S. Kim, and W. Seol (2010). Coordinate Regulation of Neurite Outgrowth by LRRK2 and Its Interactor, Rab5. Exp Neurobiol 19, 97-105.
52. M.C. Herzig, C. Kolly, E. Persohn, D. Theil, T. Schweizer, T. Hafner, C. Stemmelen, T.J. Troxler, P. Schmid, S. Danner, C.R. Schnell, M. Mueller, B. Kinzel, A. Grevot, F. Bolognani, M. Stirn, R.R. Kuhn, K. Kaupmann, P.H. van der Putten, G. Rovelli, and D.R. Shimshek (2011). LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 20, 4209-23.
53. K.M. Hinkle, M. Yue, B. Behrouz, J.C. Dächsel, S.J. Lincoln, E.E. Bowles, J.E. Beevers, B. Dugger, B. Winner, I. Prots, C.B. Kent, K. Nishioka, W.L. Lin, D.W. Dickson, C.J. Janus, M.J. Farrer, and H.L. Melrose (2012). LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener 7, 25.
54. C. Hooper, R. Killick, and S. Lovestone (2008). The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104, 1433-9.
55. K. Häbig, M. Walter, S. Poths, O. Riess, and M. Bonin (2008). RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics 9, 83-94.
56. C. Iaccarino, C. Crosio, C. Vitale, G. Sanna, M.T. Carrì, and P. Barone (2007). Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 16, 1319-26.
57. N.C. Inestrosa, and E. Arenas (2010). Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 11, 77-86.
58. N.C. Inestrosa, and E.M. Toledo (2008). The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease. Mol Neurodegener 3, 9.
59. M. Jaleel, R.J. Nichols, M. Deak, D.G. Campbell, F. Gillardon, A. Knebel, and D.R. Alessi (2007). LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405, 307-17.
60. J. Jankovic, S. Chen, and W.D. Le (2005). The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol 77, 128-38.
61. B. Jasinska-Myga, J. Kachergus, C. Vilariño-Güell, C. Wider, A.I. Soto-Ortolaza, M. Kefi, L.T. Middleton, L. Ishihara-Paul, R.A. Gibson, R. Amouri, S.B. Yahmed, S.B. Sassi, M. Zouari, G. El Euch, O.A. Ross, F. Hentati, and M.J. Farrer (2010). Comprehensive sequencing of the LRRK2 gene in patients with familial Parkinson's disease from North Africa. Mov Disord 25, 2052-8.
62. N.D. Jorgensen, Y. Peng, C.C. Ho, H.J. Rideout, D. Petrey, P. Liu, and W.T. Dauer (2009). The WD40 domain is required for LRRK2 neurotoxicity. PLoS One 4, e8463.
63. K. Kalinderi, L. Fidani, Z. Katsarou, J. Clarimón, S. Bostantjopoulou, and A. Kotsis (2011). GSK3β polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort. Neurobiol Aging 32, 546.e1-5.
64. F. Kawakami, T. Yabata, E. Ohta, T. Maekawa, N. Shimada, M. Suzuki, H. Maruyama, T. Ichikawa, and F. Obata (2012). LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One 7, e30834.
65. L.R. Kett, D. Boassa, C.C. Ho, H.J. Rideout, J. Hu, M. Terada, M. Ellisman, and W.T. Dauer (2012). LRRK2 Parkinson disease mutations enhance its microtubule association. Hum Mol Genet 21, 890-9.
66. N.L. Khan, S. Jain, J.M. Lynch, N. Pavese, P. Abou-Sleiman, J.L. Holton, D.G. Healy, W.P. Gilks, M.G. Sweeney, M. Ganguly, V. Gibbons, S. Gandhi, J. Vaughan, L.H. Eunson, R. Katzenschlager, J. Gayton, G. Lennox, T. Revesz, D. Nicholl, K.P. Bhatia, N. Quinn, D. Brooks, A.J. Lees, M.B. Davis, P. Piccini, A.B. Singleton, and N.W. Wood (2005). Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128, 2786-96.
67. Y.T. Kim, E.M. Hur, W.D. Snider, and F.Q. Zhou (2011). Role of GSK3 Signaling in Neuronal Morphogenesis. Front Mol Neurosci 4, 48.
68. H. Kitagawa, W.J. Ray, H. Glantschnig, P.V. Nantermet, Y. Yu, C.T. Leu, S. Harada, S. Kato, and L.P. Freedman (2007). A regulatory circuit mediating convergence between Nurr1 transcriptional regulation and Wnt signaling. Mol Cell Biol 27, 7486-96.
69. G. Konopka, T. Friedrich, J. Davis-Turak, K. Winden, M.C. Oldham, F. Gao, L. Chen, G.Z. Wang, R. Luo, T.M. Preuss, and D.H. Geschwind (2012). Human-specific transcriptional networks in the brain. Neuron 75, 601-17.
70. U. Kumari, and E.K. Tan (2009). LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J 276, 6455-63.
71. J.B. Kwok, M. Hallupp, C.T. Loy, D.K. Chan, J. Woo, G.D. Mellick, D.D. Buchanan, P.A. Silburn, G.M. Halliday, and P.R. Schofield (2005). GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 58, 829-39.
72. F. L'Episcopo, C. Tirolo, N. Testa, S. Caniglia, M.C. Morale, C. Cossetti, P. D'Adamo, E. Zardini, L. Andreoni, A.E. Ihekwaba, P.A. Serra, D. Franciotta, G. Martino, S. Pluchino, and B. Marchetti (2011). Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis 41, 508-27.
73. R. Le Borgne (2006). Regulation of Notch signalling by endocytosis and endosomal sorting. Curr Opin Cell Biol 18, 213-22.
74. S. Lesage, P. Ibanez, E. Lohmann, P. Pollak, F. Tison, M. Tazir, A.L. Leutenegger, J. Guimaraes, A.M. Bonnet, Y. Agid, A. Dürr, A. Brice, and F.P.s.D.G.S. Group (2005). G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 58, 784-7.
75. P.A. Lewis, and C. Manzoni (2012). LRRK2 and human disease: a complicated question or a question of complexes? Sci Signal 5, pe2.
76. Y. Li, W. Liu, T.F. Oo, L. Wang, Y. Tang, V. Jackson-Lewis, C. Zhou, K. Geghman, M. Bogdanov, S. Przedborski, M.F. Beal, R.E. Burke, and C. Li (2009). Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12, 826-8.
77. D.C. Lie, S.A. Colamarino, H.J. Song, L. Désiré, H. Mira, A. Consiglio, E.S. Lein, S. Jessberger, H. Lansford, A.R. Dearie, and F.H. Gage (2005). Wnt signalling regulates adult hippocampal neurogenesis. Nature 437, 1370-5.
78. C.H. Lin, P.I. Tsai, R.M. Wu, and C.T. Chien (2010). LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß. J Neurosci 30, 13138-49.
79. S.Y. Lin, T.Y. Li, Q. Liu, C. Zhang, X. Li, Y. Chen, S.M. Zhang, G. Lian, K. Ruan, Z. Wang, C.S. Zhang, K.Y. Chien, J. Wu, Q. Li, J. Han, and S.C. Lin (2012). GSK3-TIP60-ULK1 signaling pathway links growth factor deprivation to autophagy. Science 336, 477-81.
80. G.H. Liu, J. Qu, K. Suzuki, E. Nivet, M. Li, N. Montserrat, F. Yi, X. Xu, S. Ruiz, W. Zhang, U. Wagner, A. Kim, B. Ren, Y. Li, A. Goebl, J. Kim, R.D. Soligalla, I. Dubova, J. Thompson, J. Yates, C.R. Esteban, I. Sancho-Martinez, and J.C. Izpisua Belmonte (2012). Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491, 603-7.
81. J. Liu, X. Wu, B. Mitchell, C. Kintner, S. Ding, and P.G. Schultz (2005). A small-molecule agonist of the Wnt signaling pathway. Angew Chem Int Ed Engl 44, 1987-90.
82. F.R. Lucas, R.G. Goold, P.R. Gordon-Weeks, and P.C. Salinas (1998). Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J Cell Sci 111 (Pt 10), 1351-61.
83. F.R. Lucas, and P.C. Salinas (1997). WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons. Dev Biol 192, 31-44.
84. D. MacLeod, J. Dowman, R. Hammond, T. Leete, K. Inoue, and A. Abeliovich (2006). The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-93.
85. T. Maekawa, S. Mori, Y. Sasaki, T. Miyajima, S. Azuma, E. Ohta, and F. Obata (2012). The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities. Mol Neurodegener 7, 15.
86. P. Mangeat, C. Roy, and M. Martin (1999). ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol 9, 187-92.
87. F. Marxreiter, M. Regensburger, and J. Winkler (2012). Adult neurogenesis in Parkinson's disease. Cell Mol Life Sci.
88. I. Marín, W.N. van Egmond, and P.J. van Haastert (2008). The Roco protein family: a functional perspective. FASEB J 22, 3103-10.
89. S. Matta, K. Van Kolen, R. da Cunha, G. van den Bogaart, W. Mandemakers, K. Miskiewicz, P.J. De Bock, V.A. Morais, S. Vilain, D. Haddad, L. Delbroek, J. Swerts, L. Chávez-Gutiérrez, G. Esposito, G. Daneels, E. Karran, M. Holt, K. Gevaert, D.W. Moechars, B. De Strooper, and P. Verstreken (2012). LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 75, 1008-21.
90. A. Meixner, K. Boldt, M. Van Troys, M. Askenazi, C.J. Gloeckner, M. Bauer, J.A. Marto, C. Ampe, N. Kinkl, and M. Ueffing (2011). A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol Cell Proteomics 10, M110.001172.
91. H.L. Melrose, J.C. Dächsel, B. Behrouz, S.J. Lincoln, M. Yue, K.M. Hinkle, C.B. Kent, E. Korvatska, J.P. Taylor, L. Witten, Y.Q. Liang, J.E. Beevers, M. Boules, B.N. Dugger, V.A. Serna, A. Gaukhman, X. Yu, M. Castanedes-Casey, A.T. Braithwaite, S. Ogholikhan, N. Yu, D. Bass, G. Tyndall, G.D. Schellenberg, D.W. Dickson, C. Janus, and M.J. Farrer (2010). Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40, 503-17.
92. H.L. Melrose, C.B. Kent, J.P. Taylor, J.C. Dachsel, K.M. Hinkle, S.J. Lincoln, S.S. Mok, J.G. Culvenor, C.L. Masters, G.M. Tyndall, D.I. Bass, Z. Ahmed, C.A. Andorfer, O.A. Ross, Z.K. Wszolek, A. Delldonne, D.W. Dickson, and M.J. Farrer (2007). A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 147, 1047-58.
93. J. Milosevic, S.C. Schwarz, V. Ogunlade, A.K. Meyer, A. Storch, and J. Schwarz (2009). Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Mol Neurodegener 4, 25.
94. R.J. Nichols, N. Dzamko, J.E. Hutti, L.C. Cantley, M. Deak, J. Moran, P. Bamborough, A.D. Reith, and D.R. Alessi (2009). Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J 424, 47-60.
95. G. Paglini, P. Kunda, S. Quiroga, K. Kosik, and A. Cáceres (1998). Suppression of radixin and moesin alters growth cone morphology, motility, and process formation in primary cultured neurons. J Cell Biol 143, 443-55.
96. C. Paisán-Ruíz, S. Jain, E.W. Evans, W.P. Gilks, J. Simón, M. van der Brug, A. López de Munain, S. Aparicio, A.M. Gil, N. Khan, J. Johnson, J.R. Martinez, D. Nicholl, I.M. Carrera, A.S. Pena, R. de Silva, A. Lees, J.F. Martí-Massó, J. Pérez-Tur, N.W. Wood, and A.B. Singleton (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600.
97. K.C. Pang, M.C. Frith, and J.S. Mattick (2006). Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function. Trends Genet 22, 1-5.
98. C.L. Parish, G. Castelo-Branco, N. Rawal, J. Tonnesen, A.T. Sorensen, C. Salto, M. Kokaia, O. Lindvall, and E. Arenas (2008). Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest 118, 149-60.
99. L. Parisiadou, C. Xie, H.J. Cho, X. Lin, X.L. Gu, C.X. Long, E. Lobbestael, V. Baekelandt, J.M. Taymans, L. Sun, and H. Cai (2009). Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29, 13971-80.
100. C. Parr, R. Carzaniga, S.M. Gentleman, F. Van Leuven, J. Walter, and M. Sastre (2012). Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein. Mol Cell Biol 32, 4410-8.
101. M. Paus, Z. Kohl, N.M. Ben Abdallah, D. Galter, F. Gillardon, and J. Winkler (2012). Enhanced dendritogenesis and axogenesis in hippocampal neuroblasts of LRRK2 knockout mice. Brain Res.
102. E. Perlson, S. Maday, M.M. Fu, A.J. Moughamian, and E.L. Holzbaur (2010). Retrograde axonal transport: pathways to cell death? Trends Neurosci 33, 335-44.
103. G. Piccoli, S.B. Condliffe, M. Bauer, F. Giesert, K. Boldt, S. De Astis, A. Meixner, H. Sarioglu, D.M. Vogt-Weisenhorn, W. Wurst, C.J. Gloeckner, M. Matteoli, C. Sala, and M. Ueffing (2011). LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 31, 2225-37.
104. E.D. Plowey, S.J. Cherra, Y.J. Liu, and C.T. Chu (2008). Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 105, 1048-56.
105. S.A. Purro, L. Ciani, M. Hoyos-Flight, E. Stamatakou, E. Siomou, and P.C. Salinas (2008). Wnt regulates axon behavior through changes in microtubule growth directionality: a new role for adenomatous polyposis coli. J Neurosci 28, 8644-54.
106. A. Rajput, D.W. Dickson, C.A. Robinson, O.A. Ross, J.C. Dächsel, S.J. Lincoln, S.A. Cobb, M.L. Rajput, and M.J. Farrer (2006). Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67, 1506-8.
107. D. Ramonet, J.P. Daher, B.M. Lin, K. Stafa, J. Kim, R. Banerjee, M. Westerlund, O. Pletnikova, L. Glauser, L. Yang, Y. Liu, D.A. Swing, M.F. Beal, J.C. Troncoso, J.M. McCaffery, N.A. Jenkins, N.G. Copeland, D. Galter, B. Thomas, M.K. Lee, T.M. Dawson, V.L. Dawson, and D.J. Moore (2011). Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 6, e18568.
108. N. Rawal, O. Corti, P. Sacchetti, H. Ardilla-Osorio, B. Sehat, A. Brice, and E. Arenas (2009). Parkin protects dopaminergic neurons from excessive Wnt/beta-catenin signaling. Biochem Biophys Res Commun 388, 473-8.
109. S. Ray, and M. Liu (2012). Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design. Future Med Chem 4, 1701-13.
110. I.N. Rudenko, A. Kaganovich, D.N. Hauser, A. Beylina, R. Chia, J. Ding, D. Maric, H. Jaffe, and M.R. Cookson (2012). The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Biochem J 446, 99-111.
111. P.C. Salinas (2007). Modulation of the microtubule cytoskeleton: a role for a divergent canonical Wnt pathway. Trends Cell Biol 17, 333-42.
112. R.M. Sancho, B.M. Law, and K. Harvey (2009). Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum Mol Genet 18, 3955-68.
113. Z. Sheng, S. Zhang, D. Bustos, T. Kleinheinz, C.E. Le Pichon, S.L. Dominguez, H.O. Solanoy, J. Drummond, X. Zhang, X. Ding, F. Cai, Q. Song, X. Li, Z. Yue, M.P. van der Brug, D.J. Burdick, J. Gunzner-Toste, H. Chen, X. Liu, A.A. Estrada, Z.K. Sweeney, K. Scearce-Levie, J.G. Moffat, D.S. Kirkpatrick, and H. Zhu (2012). Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations. Sci Transl Med 4, 164ra161.
114. N. Shin, H. Jeong, J. Kwon, H.Y. Heo, J.J. Kwon, H.J. Yun, C.H. Kim, B.S. Han, Y. Tong, J. Shen, T. Hatano, N. Hattori, K.S. Kim, S. Chang, and W. Seol (2008). LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res 314, 2055-65.
115. W.W. Smith, Z. Pei, H. Jiang, V.L. Dawson, T.M. Dawson, and C.A. Ross (2006). Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9, 1231-3.
116. K. Stafa, A. Trancikova, P.J. Webber, L. Glauser, A.B. West, and D.J. Moore (2012). GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet 8, e1002526.
117. J.M. Taymans, and M.R. Cookson (2010). Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 32, 227-35.
118. K.R. Thomas, and M.R. Capecchi (1990). Targeted disruption of the murine int-1 protooncogene resulting in severe abnormalities in midbrain and cerebellar development. Nature 346, 847-50.
119. Y. Tong, E. Giaime, H. Yamaguchi, T. Ichimura, Y. Liu, H. Si, H. Cai, J.V. Bonventre, and J. Shen (2012). Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener 7, 2.
120. Y. Tong, H. Yamaguchi, E. Giaime, S. Boyle, R. Kopan, R.J. Kelleher, and J. Shen (2010). Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107, 9879-84.
121. S. Ujiie, T. Hatano, S. Kubo, S. Imai, S. Sato, T. Uchihara, S. Yagishita, K. Hasegawa, H. Kowa, F. Sakai, and N. Hattori (2012). LRRK2 I2020T mutation is associated with tau pathology. Parkinsonism Relat Disord 18, 819-23.
122. J. Van Limbergen, D.C. Wilson, and J. Satsangi (2009). The genetics of Crohn's disease. Annu Rev Genomics Hum Genet 10, 89-116.
123. M.T. Veeman, D.C. Slusarski, A. Kaykas, S.H. Louie, and R.T. Moon (2003). Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr Biol 13, 680-5.
124. T. Walston, C. Tuskey, L. Edgar, N. Hawkins, G. Ellis, B. Bowerman, W. Wood, and J. Hardin (2004). Multiple Wnt signaling pathways converge to orient the mitotic spindle in early C. elegans embryos. Dev Cell 7, 831-41.
125. S. Wang, Z.Z. Chong, Y.C. Shang, and K. Maiese (2012). WISP1 (CCN4) autoregulates its expression and nuclear trafficking of β-catenin during oxidant stress with limited effects upon neuronal autophagy. Curr Neurovasc Res 9, 91-101.
126. T. Wang, Z. Ming, W. Xiaochun, and W. Hong (2011). Rab7: role of its protein interaction cascades in endo-lysosomal traffic. Cell Signal 23, 516-21.
127. A.B. West, D.J. Moore, C. Choi, S.A. Andrabi, X. Li, D. Dikeman, S. Biskup, Z. Zhang, K.L. Lim, V.L. Dawson, and T.M. Dawson (2007). Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16, 223-32.
128. C. Wider, C. Vilariño-Güell, M.G. Heckman, B. Jasinska-Myga, A.I. Ortolaza-Soto, N.N. Diehl, J.E. Crook, S.A. Cobb, J.A. Bacon, J.O. Aasly, J.M. Gibson, T. Lynch, R.J. Uitti, Z.K. Wszolek, M.J. Farrer, and O.A. Ross (2011). SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study. Eur J Neurol 18, 876-81.
129. B. Winckler, and C.C. Yap (2011). Endocytosis and endosomes at the crossroads of regulating trafficking of axon outgrowth-modifying receptors. Traffic 12, 1099-108.
130. B. Winner, H.L. Melrose, C. Zhao, K.M. Hinkle, M. Yue, C. Kent, A.T. Braithwaite, S. Ogholikhan, R. Aigner, J. Winkler, M.J. Farrer, and F.H. Gage (2011). Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis 41, 706-16.
131. Y. Xiong, C.E. Coombes, A. Kilaru, X. Li, A.D. Gitler, W.J. Bowers, V.L. Dawson, T.M. Dawson, and D.J. Moore (2010). GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet 6, e1000902.
132. S. Zechel, A. Meinhardt, K. Unsicker, and O. von Bohlen Und Halbach (2010). Expression of leucine-rich-repeat-kinase 2 (LRRK2) during embryonic development. Int J Dev Neurosci 28, 391-9.
133. F.R. Zhang, W. Huang, S.M. Chen, L.D. Sun, H. Liu, Y. Li, Y. Cui, X.X. Yan, H.T. Yang, R.D. Yang, T.S. Chu, C. Zhang, L. Zhang, J.W. Han, G.Q. Yu, C. Quan, Y.X. Yu, Z. Zhang, B.Q. Shi, L.H. Zhang, H. Cheng, C.Y. Wang, Y. Lin, H.F. Zheng, X.A. Fu, X.B. Zuo, Q. Wang, H. Long, Y.P. Sun, Y.L. Cheng, H.Q. Tian, F.S. Zhou, H.X. Liu, W.S. Lu, S.M. He, W.L. Du, M. Shen, Q.Y. Jin, Y. Wang, H.Q. Low, T. Erwin, N.H. Yang, J.Y. Li, X. Zhao, Y.L. Jiao, L.G. Mao, G. Yin, Z.X. Jiang, X.D. Wang, J.P. Yu, Z.H. Hu, C.H. Gong, Y.Q. Liu, R.Y. Liu, D.M. Wang, D. Wei, J.X. Liu, W.K. Cao, H.Z. Cao, Y.P. Li, W.G. Yan, S.Y. Wei, K.J. Wang, M.L. Hibberd, S. Yang, X.J. Zhang, and J.J. Liu (2009). Genomewide association study of leprosy. N Engl J Med 361, 2609-18.
134. F.Q. Zhou, J. Zhou, S. Dedhar, Y.H. Wu, and W.D. Snider (2004). NGF-induced axon growth is mediated by localized inactivation of GSK-3beta and functions of the microtubule plus end binding protein APC. Neuron 42, 897-912.
135. A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer, S. Lincoln, J. Kachergus, M. Hulihan, R.J. Uitti, D.B. Calne, A.J. Stoessl, R.F. Pfeiffer, N. Patenge, I.C. Carbajal, P. Vieregge, F. Asmus, B. Müller-Myhsok, D.W. Dickson, T. Meitinger, T.M. Strom, Z.K. Wszolek, and T. Gasser (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-7.